| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5399578 (Pediatric) | NOVARTIS | Acyl compounds |
Sep, 2012
(11 years ago) | |
| US6294197 | NOVARTIS | Solid oral dosage forms of valsartan |
Jun, 2017
(6 years ago) | |
|
US6294197 (Pediatric) | NOVARTIS | Solid oral dosage forms of valsartan |
Dec, 2017
(6 years ago) | |
| US8475839 | NOVARTIS | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
May, 2023
(11 months ago) | |
| US8101599 | NOVARTIS | Pharmaceutical composition containing anti-hypertensive agents |
May, 2023
(11 months ago) | |
|
US8475839 (Pediatric) | NOVARTIS | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
Nov, 2023
(5 months ago) | |
Exforge Hct is owned by Novartis.
Exforge Hct contains Amlodipine Besylate; Hydrochlorothiazide; Valsartan.
Exforge Hct has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Exforge Hct are:
- US5399578*PED
- US6294197
- US6294197*PED
- US8475839
- US8101599
- US8475839*PED
Exforge Hct was authorised for market use on 30 April, 2009.
Exforge Hct is available in tablet;oral dosage forms.
Exforge Hct can be used as treatment of hypertension.
The generics of Exforge Hct are possible to be released after 16 November, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Apr 30, 2012 |
Drugs and Companies using AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN ingredient
Market Authorisation Date: 30 April, 2009
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
EXFORGE HCT family patents
